ANIX

HC Wainwright & Co. Reiterates Anixa Biosciences (ANIX) Buy Recommendation

Fintel reports that on September 18, 2023, HC Wainwright & Co. reiterated coverage of Anixa Biosciences (NASDAQ:ANIX) with a Buy recommendation.

Analyst Price Forecast Suggests 262.13% Upside

As of August 31, 2023, the average one-year price target for Anixa Biosciences is 12.24. The forecasts range from a low of 12.12 to a high of $12.60. The average price target represents an increase of 262.13% from its latest reported closing price of 3.38.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Anixa Biosciences is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -0.63.

What is the Fund Sentiment?

There are 63 funds or institutions reporting positions in Anixa Biosciences. This is a decrease of 3 owner(s) or 4.55% in the last quarter. Average portfolio weight of all funds dedicated to ANIX is 0.00%, a decrease of 21.25%. Total shares owned by institutions decreased in the last three months by 2.08% to 3,929K shares. ANIX / Anixa Biosciences Inc Put/Call Ratios The put/call ratio of ANIX is 0.05, indicating a bullish outlook.

What are Other Shareholders Doing?

ANIX / Anixa Biosciences Inc Shares Held by Institutions

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 928K shares representing 2.99% ownership of the company. No change in the last quarter.

UBS Group holds 634K shares representing 2.04% ownership of the company. In it's prior filing, the firm reported owning 639K shares, representing a decrease of 0.74%. The firm decreased its portfolio allocation in ANIX by 14.03% over the last quarter.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 388K shares representing 1.25% ownership of the company. In it's prior filing, the firm reported owning 365K shares, representing an increase of 5.81%. The firm decreased its portfolio allocation in ANIX by 24.63% over the last quarter.

Geode Capital Management holds 303K shares representing 0.98% ownership of the company. In it's prior filing, the firm reported owning 274K shares, representing an increase of 9.48%. The firm decreased its portfolio allocation in ANIX by 25.60% over the last quarter.

Long Focus Capital Management holds 166K shares representing 0.53% ownership of the company. No change in the last quarter.

Anixa Biosciences Background Information
(This description is provided by the company.)

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.